{"nctId":"NCT00289770","briefTitle":"Long-term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Mth Schedule in Healthy Adults","startDateStruct":{"date":"2004-11-01"},"conditions":["Hepatitis B","Hepatitis A"],"count":50,"armGroups":[{"label":"Group A","type":"EXPERIMENTAL","interventionNames":["Biological: Twinrix™"]},{"label":"Group B","type":"EXPERIMENTAL","interventionNames":["Biological: Twinrix™"]},{"label":"Group C","type":"EXPERIMENTAL","interventionNames":["Biological: Twinrix™"]}],"interventions":[{"name":"Twinrix™","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects who had consented to participate in the long-term follow-up studies at the previous long-term blood sampling time points\n* Written informed consent will have been obtained from each subject. before the blood sampling visit of each year.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With Anti-hepatitis A (Anti-HAV) Antibody Concentrations Equal to or Above Cut-off Value","description":"Cut-off value was defined as 15 milli-international units per milliliter (mIU/mL). This was considered as seropositivity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Equal to or Above Cut-off Values","description":"Cut-off values were defined 3.3 mIU/mL for the in-house anti-HBs assay and 6.2 mIU/mL for the ChemiLuminescence ImmunoAssay, which was also considered as seropositivity, and 10 mIU/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null}]}]}]},{"type":"PRIMARY","title":"Anti-HAV and Anti-HBs Antibody Concentrations","description":"Concentrations are expressed as geometric mean concentrations (GMCs) in mIU/mL.\n\nThe laboratory assay was changed from Year 13 to Year 14 to in-house ELISA and at Year 15 to CLIA for anti-HBs GMCs.Thus for the sake of bridging, blood samples corresponding to Year 14 previously tested with ELISA were re-tested with CLIA (Year 14\\*).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"680.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"602.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"601.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"524.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"610.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"458.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"475.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"163.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"149.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"242.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"210.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Anti-HBs Antibody Concentrations","description":"Subjects who lost seroprotective concentrations for anti-HBs (\\< 10 mIU/mL) at any of the LT follow-up timepoints received an additional dose of Engerix after year 15.\n\nTwo subjects were eligible for this after Year 11.\n\n3.29 in the table means a concentration of \\< 3.3 mIU/mL.\n\nAs the concentration was calculated per subject no mean concentration was calculated and also no measure of dispersion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6548.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"554.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects, Receiving an Additional Vaccination of Engerix, With an Anamnestic Response","description":"Anamnestic response was assessed in subjects receiving an additional vaccine dose of Engerix. Two subjects were found eligible at Year 11 for this additional vaccine dose.\n\nAnamnestic response was defined as:\n\n* post-additional vaccination anti-HBs concentration \\>= 10 mIU/mL in subject seronegative before additional dose.\n* 4-fold increase post-additional dose compared to pre-additional vaccine time point.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Solicited Local and General Symptoms Assessed","description":"Solicited local symptoms were pain, redness and swelling. Solicited general symptoms were fatigue, fever, gastrointestinal, headache.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Unsolicited Symptoms","description":"Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Serious Adverse Events (SAEs)","description":"SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Serious Adverse Events (SAEs) Determined by the Investigator to Have a Causal Relationship to Primary Vaccination or Due to Lack of Vaccine Efficacy","description":"SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":50},"commonTop":["Fatigue","Gastrointestinal","Heaviness sensation above eyes"]}}}